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Bovine leukaemia virus (BLV) is the aetiological agent of Leukosis enzootica bovis [Viral Oncology (1980), G. Klein (Ed.) Raven Press, New York, 
pp. 231 238], a widely spread isease in cattle. BLV is reported as the animal model of human T-cell leukaemia virus (HLTV) which is the causative 
agent of adult T-cell leukaemia nd tropical spastic paraparesis. Like the viruses themselves, the two retroviral proteinases (PR) are very closely 
related [Virology 142 (1985) 357-377]. BLV and HTLV-I PR are reported as putative proteins made of 126 [J. Virol. 57 (1986) 826 832] and 125 
[FEBS Lett. 293 (1991) 106-110] amino acids, respectively (long sequences), belonging to the aspartyl proteinase family [Nature 329 (1987) 351-354], 
with the aid of molecular modelling, we show that BLV and HLTV-I proteinases made of only 116 and 115 amino acids, respectively (short 
sequences), display three-dimensional structures similar to that observed for other retroviral aspartyl proteinases. The models are based on 
three-dimensional structures of the Rous sarcoma virus (RSV PR) and the human immunodeficiency virus (HIV-1 PR). We used solid phase peptide 
synthesis to produce the putative proteolytic enzyme of BLV (116 amino acids). In this study, we show that the folded synthetic protease accurately 
hydrolyzes a decapeptide corresponding to the sequence of the Matrice-Capside (MA/CA) cleavage site of the gag polyprotein. In addition, the 
proteolytic activity is inhibited by astatine ((4S,3S)-4-amino-3-hydroxyl-6-methylheptanoic acid) c ntaining an analogous sequence. 
BLV protease; Modelling; Solid phase synthesis; Protease activity and inhibition 
1. INTRODUCTION 
Since all known aspartic proteinases contain a con- 
served active site and core structure, it is reasonable to 
attempt to use them to model the unknown structure of 
another aspartic proteinase. The crystal structure 
knowledge of homologous proteins is useful for se- 
quence alignment and modelling of related protein. The 
crystal structures of RSV [6] and HIV-1 PR [7] were 
used to align the sequences of BLV and HTLV-I PR and 
to construct structural models of the latter. The amino 
acid sequences are shown in a structural alignment for 
RSV, BLV, HTLV-I and HIV-I proteinases in Table I. 
As described previously [5,8,9], the structure alignment 
positioned all the deletions at surface turns between 
antiparallel f strands. The carboxyl extremities of RSV 
and HIV PR are aligned with hydrophobic residues Ile 
and Leu, followed by Pro, in the long sequences of BLV 
and HTLV-I PR, respectively. Such dipeptides are 
known to belong to the privileged cleavage sites of the 
BLV and HTLV-I PR. From Pro to the carboxyl extre- 
mity, ten amino acids of the BLV and HTLV-I long 
sequences do not have any equivalent residue in the 
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alignment of the active RSV and HIV-1 PR, and subse- 
quently were not used in the modelling studies. 
2. EXPERIMENTAL 
Fig. 1 shows a stereo-view of the superimposed three-dimensional 
structures of BLV, HTLV-I and HIV PR. The model of RSV PR 
crystal structure [6], which was refined to 2.0 A, resolution with an 
agreement factor of 0.16 was used to place the main chain atoms. The 
amino acid side chains were placed either in conformation identical 
to those in RSV PR or in sterically acceptable conformations. The 
structural alignment of HTLV-I and BLV PR with RSV PR posi- 
tioned one or two short deletions at surface turns located in the regions 
25 or 7 and 25, respectively (RSV numbering). The conformations for 
the shortened loops were built as tight turns. A difficult part of the 
model building occurred at the surface loop called flap which is not 
completely visible in the electron density map of RSV PR. The model 
of the crystal structure of HIV-1 PR complexed with an inhibitor [7] 
was used to place the main and side chains of a few missing amino 
acids at the end of the flap. In such models, the ten supplementary 
residues, at the carboxyl extremity of the BLV and HTLV-I PR, would 
be located on the opposite side of the active site and would not act in 
the catalysis process. 
We used solid phase peptide synthesis to produce the short sequence, 
a 116 amino acid polypeptide of the proteolytic enzyme of BLV. The 
synthesis was performed on an Applied Biosystems 431A peptide 
synthesizer using a minimum of two coupling steps followed by a 
capping step at each addition. The protein was cleaved from the resin 
by the hydrogen fluoride (HF) procedure in presence of anisole and 
ethanethiol. The crude extract was lyophilized and purified on a Se- 
phadex G-50 column and reverse phase HPLC. The purified protein 
was analysed for composition. Furthermore, the NH2-microsequence 
analysis of fifteen amino acids was achieved by the Applied Biosystem 
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Amino acid sequence alignment for the RSV, BLV, HTLV-I and HIV-l PR. Boxes enclose regions where the BLV PR amino acid sequence is found 
conserved in other three proteinases. 
RSV 
BLV 
PVIPLDPARRPVIKAQVDTQTSHI-----KTIEALIL 
:11 ~QMW--Q!~~~;BTIKIG-~--------GML;;A~L 
I 
RSV IIISE I- EDWPTj-ij QIHGIGG W 
BLV 
HTLV 
HIV 
NWLVRD 
Ll 
rVLPQ 
40 
T v L PI1 ALFSSN KNTS- 
41 
P TVLEE KPKM- c 
_-MS__ 
RSV GIP- MmKSRDMIEmGVINRDGSLERPLLLFPAVAM 
100 
HIV F-IKVNQY-;BILIEIC-----GH -KAIGTVLVGP 
70 
0 
RSV VRGS 
BLV 
HTLV 
VG 
QIGCTLN HIV TPVN 
80 
F 
manufacturer. Both experiments confirm the identity of the BLV pro- acetonitrile by HPLC and was found to be homogenous using SDS- 
teinase. PAGE. 
The lyophilized protein was refolded with a procedure similar to the Proteolytic reactions were carried out with 10~1 of the supernatant 
one described by Tamburini et al. [lo], starting with an 8 M urea and 10~1 of a 1 mM solution of the synthetic MA/CA analog decapep- 
concentration. The three last dialysis steps versus 50-volumes of a tide containing the cleavage site Leu-Pro, Tyr-Asp-Pro-Pro-Ala-Ile- 
solution containing 100 mM sodium citrate, pH 6.2, 0.5 M sodium Leu-Pro-Be-Ile, as substrate at 37°C. Fig. 2 shows that the BLV PR 
chloride, 1 mM dithio-1,4-threitol (DTT) and 0.05% 3-[(3-cholami- can cleave the decapeptide. Two peptide products, distinct from the 
dopropyl)-dimethylammoniol-1-propanesulfonate (CHAPS), caused starting material were resolved by HPLC. The amino acid composi- 
precipitation of the unfolded proteinase. Removal of precipitated pro- tion analysis of the two peptides verified that peak 1 contains a mixture 
tein by centrifugation (20,000 x g for 30 min) yielded a soluble pro- of Pro and Ile (ratio 1:2) and peak two contains a solution of Tyr, Asp, 
teinase with a concentration ca. 1 mg/ml as determined by Bradford Ala, Ile, Leu and Pro, ratio (1,1,1,1,1:2). The same experiment was 
assay [ll]. As shown in Fig. 2, the proteinase was eluted at 60% done with the octapeptide Ser-Ile-Ser-Ile-Pro-Glu-Glu-Val, corre- 
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Fig. 1. Stereo view of the C a chains of the superimposed BLV and HTLV-I models together with the HIV-1 complexed crystal structure. For clarity, 
only three proteinases were represented: thick line, HIV-I PR; medium-thickness line, BLV PR and thin line, HTLV-I PR. The computer graphics 
program TURBO-FRODO [16] was run on the Silicon Graphics computer system. The minimization process was performed with X-PLOR [17] 
program, and required about 1,500 iterations to bring the systems to a stable state defined by a maximum derivative of the potential function < 0.01. 
sponding to our putative conformational C-terminal end of the BLV 
PR. The peptide remained uncleaved, even with increased amounts of 
BLV PR and incubation time, confirming the effective presence of ten 
more residues in the native proteinase. 
One putative statine containing inhibitor, Tyr-Asp-Pro-Pro-Ala-Ile- 
Sta-Ile-Ile, mimicking the MA/CA decapeptide substrate sequence, 
was synthesized and assayed as inhibitor for BLV PR. As shown on 
Fig. 3, as the concentration of this molecule increases, the enzymatic 
activity is inhibited. Similar experiments will be done using the recom- 
binant HTLV-I PR short sequence. 
3. RESULTS AND DISCUSSION 
The real value of our BLV PR model (short sequence) 
is underlined by the in vitro activity and inhibition of 
the synthetic proteinase. 
Of the many questions that can be raised by the 
model, the biological role of  the ten more amino acid 
residues, located at the C-terminus of the native pro- 
teinase, is of  particular interest. 
A recent work from Hayakawa et al. [12] on HTLV-I 
PR described amino acids 116-120 (HTLV-I num- 
bering) as essential to process the gag p53 precursor 
polyprotein. 
As HLTV-I and BLV PR are very closely related [2] 
a few questions still remain unanswered. Do the ten last 
amino acid residues of the two retroviral proteinases 
confer any functional advantage on the rate of enzy- 
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Fig. 2. (a) Reverse-phase HPLC of chemically synthesized BLV PR 
(116 amino acids). The proteinase applied to a Hyperbond C 18, 10 gtm 
(0.39 x 30 cm, SFCC/Shandon Scientific Ltd.) column is eluted in 30 
rain with a linear gradient, at a constant flow rate of 1 ml/min at (60:40, 
buffer A/buffer B). Buffer A: 0.08% trifluoroacetic acid (TFA) in 
acetonitrile. Buffer B: 0.1% TFA in water. The insert shows the purity 
of the HPLC peak on SDS-PAGE. The protein was silver nitrate 
stained. (b) Proteinase assays were performed at 37°C using chemi- 
cally synthesized BLV PR in 100 mM sodium citrate, pH 6.2, 0.5 M 
NaCI, 1 mM DTT and 0.05% CHAPS, followed by the separation of 
the substrate and cleavage products by reverse phase HPLC. Amino 
acid analysis of the collected peaks 1 and 2 confirms the sequences 
Pro-Ile-Ile and Tyr-Asp-Pro-Pro-Ala-Ile-Leu, respectively. 
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l ight on the possible role o f  these intr iguing supplemen-  
tary amino  acids. 
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Fig. 3. Autoradiogram of the thin layer electrophoresis analysis. Pro- 
teolytic reactions were carried out in 10/11 of a proteinase solution (1 
mg/ml), 100 mM sodium citrate, pH 6.2, 0.5 M NaC1, 1 mM DTT and 
0.05% CHAPS, containing l0 ~0 mol of the ~z~Iqabeled Tyr-Asp-Pro- 
Pro-Ala-Ile-Leu-Pro-Ile-Ile p ptide substrate. Lane 1, J25I-labeled pep- 
tide substrate; lane 2, ~251-1abeled Tyr-Asp-Pro-Pro-Ala-Ile-Leu; lane 
3, incubation at 37°C for 24 h in the presence of the peptide substrate; 
lanes 4 to 6, addition of 1 ,ul of inhibitor solutions, Tyr-Asp-Pro-Pro- 
Ala-Ile-Sta-Ile-Ile, with concentrations of 0.01, 0.1, 1 mg/ml, respec- 
tively. 
Di f ferent  means  to obta in  the BLV PR,  chemical  syn- 
thesis o f  the long sequence [13], express ion in E. coli [14], 
extract ion f rom the virus [3,15], will a l low comparat ive  
studies o f  their specific activit ies. These exper iments,  
together  with crysta l lographic  studies wou ld  shed a 
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